Literature DB >> 26739840

Spanish- and English-Speaking Pregnant Women's Views on cfDNA and Other Prenatal Screening: Practical and Ethical Reflections.

Erin Floyd1, Megan A Allyse2, Marsha Michie3.   

Abstract

The rapid clinical implementation of cell-free DNA (cfDNA) screening, a non-invasive method of prenatal genetic screening, has outpaced research on its social and ethical implications. This study is the first to compare the ethical and practical views of Spanish- and English-speaking pregnant women in the United States about cfDNA screening. Semi-structured interviews were conducted with diverse Spanish- and English-speaking women who had received prenatal care at a large academic medical center. Of the 24 interviewees, ten were Latinas who were interviewed in Spanish; English-language interviews were conducted with seven non-Hispanic Asian and seven non-Hispanic White women. Participants held positive opinions concerning the accuracy of cfDNA screening and often noted that it would enhance preparedness. Participants also expressed concerns about the possibility of inaccurate results and the potentially negative effects of cfDNA screening on the experience of pregnancy. Differences emerged between Spanish and English speakers in their portrayals of their relationships with prenatal health care providers, the extent to which they questioned providers' advice, their ethical concerns, and their informational needs. We emphasize the importance of customizing prenatal test counseling to the needs of the individual patient, providing educationally appropriate counseling and literature, and mitigating potential language barriers.

Entities:  

Keywords:  Ethics; Latinas; NIPS; NIPT; Prenatal screening; Spanish-speakers; cfDNA; cfDNA screening

Mesh:

Year:  2016        PMID: 26739840      PMCID: PMC4936962          DOI: 10.1007/s10897-015-9928-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  54 in total

1.  Disparities in health care by race, ethnicity, and language among the insured: findings from a national sample.

Authors:  Kevin Fiscella; Peter Franks; Mark P Doescher; Barry G Saver
Journal:  Med Care       Date:  2002-01       Impact factor: 2.983

2.  Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy.

Authors:  Julie M H Horsting; Stephen R Dlouhy; Katelyn Hanson; Kimberly Quaid; Shaochun Bai; Karrie A Hines
Journal:  J Genet Couns       Date:  2013-12-19       Impact factor: 2.537

3.  "Don't Want No Risk and Don't Want No Problems": Public Understandings of the Risks and Benefits of Non-Invasive Prenatal Testing in the United States.

Authors:  Megan Allyse; Lauren Carter Sayres; Taylor Goodspeed; Marsha Michie; Mildred K Cho
Journal:  AJOB Empir Bioeth       Date:  2015

4.  Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake.

Authors:  Reana Tischler; Louanne Hudgins; Yair J Blumenfeld; Henry T Greely; Kelly E Ormond
Journal:  Prenat Diagn       Date:  2011-10-26       Impact factor: 3.050

5.  Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services.

Authors:  Robert Currier; Nerissa Wu; Karla Van Meter; Sara Goldman; Fred Lorey; Monica Flessel
Journal:  Prenat Diagn       Date:  2012-08-18       Impact factor: 3.050

Review 6.  Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy.

Authors: 
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

7.  Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening.

Authors:  Shilpa Chetty; Matthew J Garabedian; Mary E Norton
Journal:  Prenat Diagn       Date:  2013-06       Impact factor: 3.050

8.  NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability.

Authors:  Joanne B Taylor; Valerie Y Chock; Louanne Hudgins
Journal:  J Genet Couns       Date:  2013-05-31       Impact factor: 2.537

9.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

10.  Primary language and receipt of recommended health care among Hispanics in the United States.

Authors:  Eric M Cheng; Alex Chen; William Cunningham
Journal:  J Gen Intern Med       Date:  2007-11       Impact factor: 5.128

View more
  6 in total

1.  Perspectives of Pregnant People and Clinicians on Noninvasive Prenatal Testing: A Systematic Review and Qualitative Meta-synthesis.

Authors:  Meredith Vanstone; Alexandra Cernat; Umair Majid; Forum Trivedi; Chanté De Freitas
Journal:  Ont Health Technol Assess Ser       Date:  2019-02-19

Review 2.  Latinx individuals' knowledge of, preferences for, and experiences with prenatal genetic testing: a scoping review.

Authors:  Natalie Grafft; Andrew A Dwyer; María Pineros-Leano
Journal:  Reprod Health       Date:  2022-06-06       Impact factor: 3.355

3.  Is preparation a good reason for prenatal genetic testing? Ethical and critical questions.

Authors:  Marsha Michie
Journal:  Birth Defects Res       Date:  2020-03-01       Impact factor: 2.344

4.  Genetic counseling and testing for Asian Americans: a systematic review.

Authors:  Jennifer L Young; Julie Mak; Talia Stanley; Michelle Bass; Mildred K Cho; Holly K Tabor
Journal:  Genet Med       Date:  2021-05-10       Impact factor: 8.822

5.  Pregnant Hispanic women's views and knowledge of prenatal genetic testing.

Authors:  Robin L Page; Christina Murphey; Yahyahan Aras; Lei-Shih Chen; Ryan Loftin
Journal:  J Genet Couns       Date:  2021-01-26       Impact factor: 2.537

6.  Women's perspectives on the ethical implications of non-invasive prenatal testing: a qualitative analysis to inform health policy decisions.

Authors:  Meredith Vanstone; Alexandra Cernat; Jeff Nisker; Lisa Schwartz
Journal:  BMC Med Ethics       Date:  2018-04-16       Impact factor: 2.652

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.